◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › N › NKTR

Nektar Therapeutics (NKTR) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-04

Nektar Therapeutics (NKTR) operates in the BIOTECHNOLOGY industry and is headquartered in San Francisco, United States with about 63 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, NKTR reported $55M in revenue and ($164M) in net income.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

Interactive charts & full statements → Open the NKTR valuation workbench →

NKTR Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$55M	$55M	$98M	$90M	$92M	$102M	$153M	$115M	$1.2B	$308M	$165M	$231M	$201M	$149M	$81M	$71M	$159M	$72M	$90M	$273M	$218M
Operating Income (EBIT)	($131M)	($131M)	($105M)	($137M)	($240M)	($446M)	($380M)	($440M)	$688M	($60M)	($113M)	($29M)	($16M)	($120M)	($141M)	($124M)	($28M)	($95M)	($83M)	($36M)	($159M)
Operating Margin %	-238.2%	-236.8%	-106.9%	-152.5%	-261.0%	-437.8%	-248.5%	-383.9%	57.6%	-19.4%	-68.2%	-12.7%	-8.2%	-80.7%	-173.9%	-173.4%	-17.8%	-132.2%	-91.6%	-13.2%	-73.1%
Net Income	($158M)	($164M)	($119M)	($276M)	($368M)	($524M)	($444M)	($441M)	$681M	($97M)	($154M)	($81M)	($54M)	($162M)	($172M)	($134M)	($38M)	($103M)	($34M)	($33M)	($155M)
Net Margin %	-287.3%	-297.1%	-120.9%	-306.3%	-400.0%	-514.0%	-290.6%	-384.5%	57.1%	-31.4%	-92.8%	-35.2%	-26.9%	-108.8%	-211.7%	-187.4%	-23.8%	-142.5%	-38.1%	-12.0%	-71.1%
EBITDA	($134M)	($137M)	($87M)	($243M)	($324M)	($462M)	($394M)	($383M)	$734M	($43M)	($97M)	($29M)	($3M)	($106M)	($124M)	($108M)	($9M)	($76M)	$3M	($7M)	($126M)
Earnings Per Share (EPS)	$-7.35	$-9.73	$-8.68	$-21.79	$-29.51	$-42.87	$-37.33	$-37.77	$56.74	$-9.30	$-16.50	$-9.19	$-6.37	$-21.00	$-22.45	$-17.79	$-6.05	$-16.58	$-5.57	$-5.35	$-25.85
Shares Outstanding (M)	33M	17M	14M	13M	12M	12M	12M	12M	12M	10M	9M	9M	8M	8M	8M	8M	6M	6M	6M	6M	6M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NKTR Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$10M	$11M	$22M	$12M	$11M	$10M	$29M	$24M
Operating Income (EBIT)	($42M)	($38M)	($19M)	($32M)	($36M)	($45M)	$14M	($34M)
Operating Margin %	-417.9%	-352.2%	-87.5%	-267.4%	-324.2%	-425.8%	49.2%	-142.4%
Net Income	($41M)	($45M)	($36M)	($36M)	($42M)	($51M)	$7M	($37M)
Net Margin %	-401.0%	-413.4%	-165.5%	-301.3%	-372.2%	-486.4%	24.9%	-153.6%
EBITDA	($42M)	($37M)	($26M)	($29M)	($34M)	($41M)	$17M	($30M)
Earnings Per Share (EPS)	$-1.23	$-1.82	$-1.78	$-2.52	$-2.95	$-3.62	$0.51	$-2.66
Shares Outstanding (M)	33M	25M	20M	14M	14M	14M	14M	14M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NKTR Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($234M)	($209M)	($176M)	($193M)	($304M)	($413M)	($313M)	($329M)	$718M	($80M)	($117M)	($73M)	($142M)	($39M)	($130M)	($114M)	($56M)	$40M	($146M)	$146M	($93M)
Capital Expenditures (CapEx)	$0M	$0M	$1M	$1M	$6M	$15M	$7M	$26M	$14M	$10M	$6M	$11M	$10M	$4M	$11M	$10M	$31M	$21M	$19M	$33M	$23M
Free Cash Flow (FCF)	($234M)	($209M)	($177M)	($193M)	($310M)	($428M)	($321M)	($355M)	$704M	($90M)	($123M)	($84M)	($152M)	($43M)	($140M)	($123M)	($87M)	$19M	($165M)	$114M	($115M)
FCF Margin %	-425.5%	-377.8%	-180.0%	-214.7%	-336.4%	-419.7%	-209.6%	-309.7%	59.0%	-29.3%	-74.6%	-36.5%	-75.7%	-28.6%	-172.8%	-172.7%	-54.9%	26.5%	-182.5%	41.6%	-52.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NKTR Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($76M)	($44M)	($65M)	($49M)	($46M)	($49M)	($46M)	($44M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M
Free Cash Flow (FCF)	($76M)	($44M)	($65M)	($49M)	($46M)	($49M)	($47M)	($45M)
FCF Margin %	-749.0%	-408.0%	-298.0%	-414.6%	-409.6%	-469.0%	-159.9%	-184.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NKTR Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$1.1B	$280M	$304M	$398M	$711M	$1.1B	$1.5B	$2.0B	$2.1B	$509M	$569M	$502M	$442M	$435M	$498M	$607M	$521M	$576M	$561M	$725M	$768M
Cash & Cash Equivalents	$39M	$15M	$44M	$35M	$88M	$25M	$199M	$96M	$195M	$5M	$60M	$56M	$12M	$39M	$25M	$15M	$18M	$50M	$156M	$76M	$64M
Total Liabilities	$192M	$191M	$243M	$267M	$344M	$438M	$461M	$572M	$433M	$421M	$481M	$496M	$405M	$524M	$451M	$409M	$431M	$473M	$370M	$511M	$541M
Total Debt (Short + Long-Term)	$23M	$20M	$20M	$19M	$19M	$17M	$14M	$265M	$309M	$277M	$249M	$252M	$130M	$169M	$166M	$232M	$262M	$262M	$274M	$339M	$438M
Total Shareholders' Equity	$903M	$90M	$61M	$131M	$367M	$680M	$1.1B	$1.4B	$1.7B	$88M	$88M	$6M	$36M	($90M)	$47M	$198M	$91M	$102M	$190M	$214M	$227M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NKTR viewer.

Other Companies in BIOTECHNOLOGY

MLYS · Mineralys Therapeutics, Inc. Common Stock — $2 billion
VERA · Vera Therapeutics Inc — $2 billion
HRMY · Harmony Biosciences Holdings — $2 billion
SLS · Sellas Life Sciences Group Inc — $2 billion
AUPH · Aurinia Pharmaceuticals Inc — $2 billion
GENB · Generate Biomedicines, Inc. Common Stock — $2 billion
OCUL · Ocular Therapeutix Inc — $2 billion
PVLA · Palvella Therapeutics, Inc — $2 billion

← NKT All “N” companies NKTX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.